A Phase II Randomized, Double-Blind, Placebo-Controlled Study of Simtuzumab or Placebo in Combination with Gemcitabine for the First-Line Treatment of Pancreatic Adenocarcinoma
Al B Benson 3rd, Zev A Wainberg, J Randolph Hecht, Dmitry Vyushkov, Hua Dong, Johanna Bendell, Fred Kudrik, Al B Benson 3rd, Zev A Wainberg, J Randolph Hecht, Dmitry Vyushkov, Hua Dong, Johanna Bendell, Fred Kudrik
Abstract
Lessons learned: The safety profile in the gemcitabine/simtuzumab group was similar to that in the gemcitabine/placebo group.The addition of simtuzumab to gemcitabine does not improve clinical outcomes in patients with metastatic pancreatic adenocarcinoma ABSTRACT: Background.The humanized IgG4 monoclonal antibody simtuzumab inhibits the extracellular matrix-remodeling enzyme lysyl oxidase-like 2 maintaining pathological stroma in tumors.
Methods: Adult patients with metastatic pancreatic adenocarcinoma (mPaCa) were randomly assigned to receive intravenous gemcitabine, 1,000 mg/m2, in combination with 200 or 700 mg simtuzumab or placebo. Primary endpoint was progression-free survival (PFS), secondary endpoints included overall survival (OS), objective response rate (ORR), and safety.
Results: Of 240 patients, 80 were randomly assigned to gemcitabine/simtuzumab 700 mg, 79 to gemcitabine/simtuzumab 200 mg, and 81 to gemcitabine/placebo. After a median follow-up of 3.0, 1.9, and 3.4 months for gemcitabine/simtuzumab 700 mg, gemcitabine/simtuzumab 200 mg, and gemcitabine/placebo, respectively, the median PFS was 3.7 months (adjusted hazard ratio [HR], 95% confidence interval [CI], p value vs placebo: 1.09 [0.74-1.61]; p = .73), 3.5 months (1.13 [0.76-1.66], p = .61]), and 3.7 months, respectively. Median OS was 7.6 months (0.83 [0.57-1.22]; p = .28), 5.9 months (1.07 [0.73-1.55]; p = .69), and 5.7 months, respectively. ORRs were 13.9%, 14.5%, and 23.5%, respectively. Simtuzumab was well tolerated.
Conclusion: The addition of simtuzumab to gemcitabine did not improve clinical outcomes in patients with mPaCa. The Oncologist 2017;22:241-e7.
Trial registration: ClinicalTrials.gov NCT01472198.
© AlphaMed Press; the data published online to support this summary is the property of the authors.
Figures
References
- Ferlay J, Soerjomataram I, Dikshit R et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015;136:E359–386.
- Pancreatic Cancer Facts . 2015. Pancreatic Cancer Action Network. Available at . Accessed May 12, 2016.
- Chu GC, Kimmelman AC, Hezel AF et al. Stromal biology of pancreatic cancer. J Cell Biochem 2007;101:887–907.
- Farrow B, Albo D, Berger DH. The role of the tumor microenvironment in the progression of pancreatic cancer. J Surg Res 2008;149:319–328.
- National Comprehensive Cancer Network . NCCN Clinical Practice Guidelines in Oncology. Pancreatic adenocarcinoma. 2016. Available at . Accessed May 12, 2016.
- Barry‐Hamilton V, Spangler R, Marshall D et al. Allosteric inhibition of lysyl oxidase‐like‐2 impedes the development of a pathologic microenvironment. Nat Med 2010;16:1009–1017.
- Fong SF, Dietzsch E, Fong KS et al. Lysyl oxidase‐like 2 expression is increased in colon and esophageal tumors and associated with less differentiated colon tumors. Genes Chromosomes Cancer 2007;46:644–‐655.
- Benson A, Bendell J, Wainberg Z et al. A phase 2 randomized, double‐blind, placebo controlled study of simtuzumab or placebo in combination with gemcitabine for the first line treatment of pancreatic adenocarcinoma. Ann Oncol 2014;25;iv210–iv253.
- Zaffryar‐Eilot S, Marshall D, Voloshin T et al. Lysyl oxidase‐like‐2 promotes tumour angiogenesis and is a potential therapeutic target in angiogenic tumours. Carcinogenesis 2013;34:2370–2379.
- Payne SL, Hendrix MJ, Kirschmann DA. Paradoxical roles for lysyl oxidases in cancer—a prospect. J Cell Biochem 2007;101:1338–1354.
- Rodriguez HM, Vaysberg M, Mikels A et al. Modulation of lysyl oxidase‐like 2 enzymatic activity by an allosteric antibody inhibitor. J Biol Chem 2010;285:20964–20974.
- Van Bergen T, Marshall D, Van de Veire S et al. The role of LOX and LOXL2 in scar formation after glaucoma surgery. Invest Ophthalmol Vis Sci 2013;54:5788–5796.
- Peng L, Ran YL, Hu H et al. Secreted LOXL2 is a novel therapeutic target that promotes gastric cancer metastasis via the Src/FAK pathway. Carcinogenesis 2009;30:1660–1669.
- LoRusso P, Hecht J, Thai D et al. Phase I and IIa studies of simtuzumab alone and in combination with FOLFIRI in patients with advanced solid tumors. J Clin Oncol 2014;32:abstract 554.
Source: PubMed